Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
US12304906B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12304906-B2 |
| Application number | US-202017787369-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 7, 2020 |
| Priority date | Dec 24, 2019 |
| Publication date | May 20, 2025 |
| Grant date | May 20, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method for preparing lurasidone hydrochloride by reacting lurasidone free alkali reacts with hydrochloric acid in a mixed solvent of an alcoholic solvent and an alkyl halide solvent.
Opening claim text (preview).
The invention claimed is: 1. A method for preparing lurasidone hydrochloride, comprising: heating and dissolving lurasidone free base in a mixed solvent of alcoholic solvent and dichloromethane, adding hydrochloric acid solution to carry out a salt-forming reaction; and cooling, crystallizing, filtering and drying to obtain lurasidone hydrochloride. 2. The method according to claim 1 , wherein the alcoholic solvent is one or more of methanol, ethanol, isopropanol, n-propanol, n-butanol, sec-butanol, isobutanol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,4-butanediol, 2,3-butanediol, 1,5-pentanediol, 1,6-hexanediol and glycerol. 3. The method according to claim 2 , wherein the alcoholic solvent is selected from the group consisting of methanol, ethanol, and isopropanol. 4. The method according to claim 1 , wherein the concentration of the hydrochloric acid solution is from 0.3% (w/w) to saturated concentration. 5. The method according to claim 4 , wherein the concentration of the hydrochloric acid solution is 15% to 38% (w/w). 6. The method according to claim 1 , wherein the molar ratio of hydrogen chloride in the hydrochloric acid solution to lurasidone free base is 20:1 to 1:1. 7. The method according to claim 6 , wherein the molar ratio of hydrogen chloride in the hydrochloric acid solution to lurasidone free base is 10:1 to 1:1. 8. The method according to claim 1 , wherein the hydrochloric acid solution is an aqueous hydrochloric acid solution, or a solution formed by mixing an aqueous hydrochloric acid solution with an appropriate amount of the alcoholic solvent. 9. The method according to claim 1 , wherein the mass-to-volume ratio of lurasidone free base to the alcoholic solvent in the reaction system is 1:5 to 1:50 (W/V). 10. The method according to claim 1 , wherein the mass-to-volume ratio of lurasidone free base to dichloromethane is 1:0.5 to 1:10 (W/V). 11. The method according to claim 9 , wherein the mass-to-volume ratio of lurasidone free base to the alcoholic solvent in the reaction system is 1:8 to 1:15 (W/V). 12. The method according to claim 10 , wherein the mass-to-volume ratio of lurasidone free base to dichloromethane is 1:1 to 1:4 (W/V).
Spiro-condensed systems · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a carbon chain containing alicyclic rings · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.